The sudden push is puzzling, as cannabis legislation tends to move under House Democrats—and get stalled by Senate Republicans.
Lawmakers, agriculture regulators, and hemp industry stakeholders have been calling for more time to get up to speed with the USDA’s new hemp regulations.
Supporters of the bill to remove cannabis from the Controlled Substances Act expressed frustration and disappointment.
The next step for the bill, which would expand cannabis research in the US, is the full House.
"I’m pleased to bring the MORE Act to the House Floor next month to decriminalize marijuana at the federal level," House Majority Leader Steny Hoyer told Cannabis Wire.
While the MORE Act stands a solid chance of passage in the Democrat-controlled House, the Senate is another story.
The protections range from expanding banking access to preventing federal interference in states with legal cannabis, but passage in the Senate is uncertain.
An official in the Department’s Antitrust Division said during a House Judiciary Committee hearing that cannabis is “unpopular” with Barr, and therefore he influenced investigations.
An official in the Department’s antitrust division will testify before Congress on Wednesday that Barr’s “personal dislike” of cannabis influenced investigations.
The SAFE Banking Act has been included in the HEROES Act. Whether the language will survive the Senate is another question.
Two letters—one signed by cannabis trade groups, the other by groups focused on justice—were sent this week pushing Congress for COVID-19 relief for cannabis businesses.
As cannabis remains federally illegal, state-legal cannabis businesses have been left out of COVID-19 relief funds.
Oregon Senator Ron Wyden and others argue that now is a good time for the Small Business Administration to pull out of its “time warp” and help these struggling small firms.
The House Committee on Veterans Affairs voted in support of medical cannabis access and research, sending two bills to the full House.
The FDA is reopening public comment, collaborating with global regulators on how to handle cannabinoids, and backing research on CBD and “dermal penetration.”
DEA says legislation pending White House approval would pave the way for new, federally-approved research-grade cannabis farms.